HC Wainwright set a $38.00 price objective on Stemline Therapeutics (NASDAQ:STML) in a report published on Thursday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on STML. BidaskClub cut Stemline Therapeutics from a buy rating to a hold rating in a report on Thursday, December 7th. Cowen reaffirmed a buy rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $33.75.

Shares of Stemline Therapeutics (STML) traded up $0.05 during mid-day trading on Thursday, hitting $14.75. The stock had a trading volume of 602,463 shares, compared to its average volume of 274,765. Stemline Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $16.00.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lyon Street Capital LLC raised its holdings in shares of Stemline Therapeutics by 331.1% during the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after acquiring an additional 415,867 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Stemline Therapeutics by 32.9% in the first quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock valued at $7,055,000 after purchasing an additional 204,228 shares in the last quarter. AXA grew its position in shares of Stemline Therapeutics by 44.9% in the second quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock valued at $5,789,000 after purchasing an additional 195,022 shares in the last quarter. C WorldWide Group Holding A S purchased a new stake in shares of Stemline Therapeutics in the third quarter valued at approximately $1,776,000. Finally, Artal Group S.A. grew its position in shares of Stemline Therapeutics by 150.0% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $2,300,000 after purchasing an additional 150,000 shares in the last quarter. 50.24% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/stemline-therapeutics-stml-given-a-38-00-price-target-at-hc-wainwright/1766658.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.